ARID1A、前列腺素E2及其受体作为子宫内膜异位症中子宫内膜恶性转化的可能预测指标

ARID1A, Prostaglandin E2, and Its Receptor as Possible Predictors of Malignant Transformation of the Endometrium in Endometriosis.

作者信息

Dyatlova A S, Lin'kova N S, Polyakova V O, Samoshkin N G, Kvetnoi I M

机构信息

Department of Biogerontology, Research Center St. Petersburg Institute of Bioregulation and Gerontology, St. Petersburg, Russia.

Department of Therapy, Geriatrics, and Anti-Age Medicine, Academy of Postgraduate Education, Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies, Federal Medical-Biological Agency, Moscow, Russia.

出版信息

Bull Exp Biol Med. 2019 Aug;167(4):504-507. doi: 10.1007/s10517-019-04560-7. Epub 2019 Sep 7.

DOI:10.1007/s10517-019-04560-7

PMID:31494765

Abstract

We studied the expression of ARID1A, prostaglandin E2 synthase, and prostaglandin E2 receptor in the endometrium and ovarian, peritoneal, and intestinal endometrioid heterotopies in women with endometriosis of young and middle reproductive age. ARID1A protein is a tumor suppressor, its expression reduced in different types of cancer. Prostaglandin E2 synthase and prostaglandin E2 receptor are involved in the signaling cascade of inflammatory reactions presumably underlying the development of endometriosis. In endometrioid heterotopies, expression of ARID1A was reduced in 1.2-4.0 times, the expression of prostaglandin E2 synthase and prostaglandin E2 receptor was reduced in 2.9-5.2 times These findings suggest that ARID1A, prostaglandin E2 synthase, and prostaglandin E2 receptor can be used as predictors of malignant transformation of endometrioid heterotopies in women with endometriosis.

摘要

我们研究了年轻及中年育龄期子宫内膜异位症女性子宫内膜以及卵巢、腹膜和肠道子宫内膜样异位灶中ARID1A、前列腺素E2合成酶和前列腺素E2受体的表达情况。ARID1A蛋白是一种肿瘤抑制因子，其表达在不同类型癌症中降低。前列腺素E2合成酶和前列腺素E2受体参与了可能是子宫内膜异位症发病基础的炎症反应信号级联。在子宫内膜样异位灶中，ARID1A的表达降低了1.2至4.0倍，前列腺素E2合成酶和前列腺素E2受体的表达降低了2.9至5.2倍。这些发现表明，ARID1A、前列腺素E2合成酶和前列腺素E2受体可作为子宫内膜异位症女性子宫内膜样异位灶恶性转化的预测指标。